About Us

Red Tree Venture Capital is an early stage-biased life science venture firm that employs a targeted strategy of leveraging its deep relationships with leading West Coast academic and research institutions to source innovation emerging from those organizations. The firm closed its inaugural fund, Red Tree Venture Capital Fund I, in 2022, raising a total of $272 million to create and/or invest in life science companies that are advancing transformative science.

Our team pairs a proven ability to translate scientific innovation into successful businesses with unique access to premier West Coast academic luminaries and scientific entrepreneurs. This combination strongly positions Red Tree Venture Capital to establish itself as the partner-of-choice for West Coast entrepreneurs and scientists looking to create and build impactful life science companies.

Augmenting the Red Tree Venture Capital team is a scientific advisory board of academic thought leaders affiliated with some of the West Coast’s most prestigious institutions. These individuals, who include department chairs, division chiefs and institute heads, are also established entrepreneurs collectively credited with founding more than 25 companies. Further supplementing the firm’s leadership is a team of senior advisors comprised of experienced biopharma executives that provide Red Tree broad expertise across key aspects of the life science industry, including company creation/building, business operations and drug development.